VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | Pivotal safety and efficacy results for liso-cel in R/R B-NHL

Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, discusses the pivotal safety and efficacy results from the TRANSCEND-NHL-001 study (NCT02631044). This is a phase I study evaluating lisocabtagene maraleucel (liso-cel), an investigational, anti-CD19 CAR T-cell product, in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Abramson highlights the very encouraging results, including durable clinical activity and a favorable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter